Additionally, loss of Smad4 staining was a significant prognostic marker for a poor outcome in different cancers (cervical carcinoma, colorectal cancer, gastric cancer and pancreatic cancer), regardless of the number of participants (small or large). Here, SMAD4 is linked to pancreatic neoplasm.